STOCK TITAN

ICON Public Limited Company - ICLR STOCK NEWS

Welcome to our dedicated page for ICON Public Company news (Ticker: ICLR), a resource for investors and traders seeking the latest updates and insights on ICON Public Company stock.

ICON plc (ICLR) is a leading global provider of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. Headquartered in Ireland, ICON specializes in the strategic development, management, and analysis of clinical programs that support clinical development from compound selection to phase I-IV clinical studies.

Operating in a highly fragmented industry, ICON is among a select group of organizations with the capability and expertise to conduct clinical trials and development projects on both a local and global scale. The company's core services are versatile, offering both standalone and integrated full-service solutions to meet diverse client needs. This operational flexibility ensures that ICON can tailor its services to individual project requirements.

ICON's array of services includes end-to-end pharmacovigilance, which covers post-marketing surveillance activities. The company also provides ancillary services, such as laboratory and imaging capabilities, enhancing its comprehensive approach to drug development and clinical research.

This robust service offering positions ICON as a pivotal partner for firms aiming to bring their medical innovations to market. Recent achievements and ongoing projects underscore ICON's commitment to excellence and innovation in clinical research. The company's financial health remains strong, supported by strategic partnerships and a global client base.

Stay updated on ICON plc's latest developments, performance updates, and industry news to understand the significant role this organization plays in advancing healthcare solutions worldwide.

Rhea-AI Summary

ICON (NASDAQ: ICLR), a leading healthcare intelligence and clinical research organization, has been recognized with multiple awards in the first half of 2024 for its leadership in clinical research, inclusion, sustainability, and as a top employer. At the CRO Leadership Awards 2024, ICON excelled in all categories, receiving individual accolades for data quality, project timelines, operational excellence, and technology. ICON's AI solution, Cassandra, was lauded at the Citeline 2024 awards for its innovative use of real-world data. The company was named Clinical Research Company of the Year at the PharmaTimes International Clinical Researcher of the Year awards, and its site network, Accellacare, won Best Clinical Trial Network at the Vaccine Industry Excellence Awards. HumanFirst, recently acquired by ICON, was named Best Clinical Trial Technology Solution Provider at the MedTech Breakthrough Awards 2024. ICON also received a Viddy Award for its digital services and was named Social & Equality Business of the Year at the PwC Business Post Sustainable Business Awards. Additionally, ICON was listed among Europe’s Climate Leaders in 2024 by the Financial Times and recognized as a top workplace in Ireland by LinkedIn.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
-
Rhea-AI Summary

ICON plc (NASDAQ: ICLR), a global leader in healthcare intelligence and clinical research, has announced the release of its second quarter 2024 financial results. The results will be disclosed after market hours on July 24, 2024. A conference call and webcast to discuss these results are scheduled for July 25, 2024, at 8:00am ET. Updates and links to the live webcast will be available on the Investor section of ICON's website under 'Events.' A replay of the webcast will be accessible approximately an hour after the call concludes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.57%
Tags
conference call earnings
-
Rhea-AI Summary

ICON plc (NASDAQ: ICLR), a prominent healthcare intelligence and clinical research organization, has announced that its CEO, Dr. Steve Cutler, will present at the Jefferies Global Healthcare Conference. The event will take place on Thursday, June 6, 2024, at 1:30pm ET. The live webcast and any updates regarding this event will be accessible through the Investor section of the company's website under 'Events'. This presentation underscores ICON's ongoing efforts to engage with investors and stakeholders, showcasing its leadership and innovation in the healthcare sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.67%
Tags
conferences
Rhea-AI Summary

ICON (NASDAQ: ICLR) will host its 2024 Investor Day in New York City, featuring presentations from its executive team outlining strategic initiatives and financial outlook. ICON updated its 2024 guidance, expecting adjusted earnings per share (EPS) to range between $14.75 and $15.25, representing a 15.3% to 19.2% increase over 2023. Full-year revenue is projected to be between $8,480 million and $8,720 million, marking a 4.4% to 7.4% year-over-year increase. The company has also refined its debt structure, including a $2 billion bond offering and Term Loan B repricing, which is expected to result in a net interest expense of $200-$210 million in 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.33%
Tags
none
-
Rhea-AI Summary

ICON, a leading healthcare intelligence and clinical research organization, has announced an Investor Day event on May 30, 2024, in New York City. Starting at 10 AM ET, the event will feature presentations from ICON's executive team and a question-and-answer session, concluding around 1 PM ET. A live webcast of the event will be available on ICON's Investor section of their website. Any updates or changes will also be posted there.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
none
-
News
Rhea-AI Summary

ICON plc, a healthcare intelligence and clinical research organization, released its ICON Cares 2023 Report. The report highlights the company's achievements in ESG, diversity, inclusion, and sustainability goals. ICON received recognition for its efforts, including a gold medal status from EcoVadis and being named one of Europe's Climate Leaders in 2024. The company focused on increasing access to clinical trials, promoting workplace diversity, conducting business sustainably, and supporting communities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.06%
Tags
none
Rhea-AI Summary

ICON plc announced the pricing of a USD 2 billion SEC-registered bond offering, consisting of three tranches with varying maturity dates. The Notes will be issued by ICON's subsidiary and guaranteed by ICON and its subsidiaries. The offering is expected to close on May 8, 2024, with proceeds used to repay existing debt and cover related expenses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
-
News
Rhea-AI Summary
ICON plc (NASDAQ: ICLR) reported strong first quarter 2024 results with $2,654 million in net business wins and a closing backlog of $23.4 billion. Revenue increased by 5.7% year over year to $2,090.4 million. Adjusted EBITDA rose by 11.3% to $444.0 million. GAAP net income increased by 59.6% to $187.4 million. Adjusted net income grew by 19.7% to $288.5 million. The company updated its full-year 2024 financial guidance with revenue expected to be in the range of $8,480 - $8,720 million and adjusted earnings per share in the range of $14.65 - $15.15.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
-
News
Rhea-AI Summary
ICON plc (ICLR) announces Chief Financial Officer's departure for a new opportunity. The company reaffirms its full year 2024 guidance with revenue expected to be $8,400 - $8,800 million and adjusted earnings per share in the range of $14.50 - $15.30.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
none
Rhea-AI Summary
ICON plc (ICLR) to announce first quarter 2024 financial results on April 24, 2024, followed by a conference call on April 25, 2024. Webcast details will be available on the Investor section of the website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.03%
Tags

FAQ

What services does ICON plc provide?

ICON plc provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries, including clinical trial management, laboratory, and imaging capabilities.

Where is ICON plc headquartered?

ICON plc is headquartered in Ireland.

What is ICON's role in pharmaceutical development?

ICON specializes in the strategic development, management, and analysis of clinical programs, supporting clinical development from compound selection to phase I-IV clinical studies.

Does ICON offer standalone and integrated services?

Yes, ICON provides both standalone and integrated full-service solutions to meet diverse client needs.

What is pharmacovigilance, and does ICON provide it?

Pharmacovigilance involves monitoring the effects of drugs after they have been licensed for use to ensure they are safe. ICON offers end-to-end pharmacovigilance services, including post-marketing surveillance.

What industries does ICON serve?

ICON serves the pharmaceutical, biotechnology, and medical device industries.

What makes ICON a leader in its industry?

ICON's capability to conduct clinical trials globally, strong financial health, strategic partnerships, and comprehensive service offerings make it a leader in the industry.

How can I stay updated on ICON's latest news and developments?

You can stay updated on ICON's latest news and developments by visiting reputable stock market websites or ICON's official website.

What are some of ICON's ancillary services?

ICON offers ancillary services, including laboratory and imaging capabilities, to support drug development and clinical research.

What type of clients does ICON work with?

ICON works with clients in the pharmaceutical, biotechnology, and medical device industries, providing them with comprehensive development and clinical trial services.

ICON Public Limited Company

Nasdaq:ICLR

ICLR Rankings

ICLR Stock Data

28.14B
82.68M
0.65%
99.69%
2.54%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Dublin 18